SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 18 of 21
Word Count: 1409
Character Count: 8809

Document Content:

or Option Shares to which a default relates as provided in this Section 6, this Agreement will automatically be terminated by you or the Company without liability on the part of the Company (except as provided in Sections 3.10 and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof); provided, however, that if such default occurs with respect to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided, further, that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder. For the avoidance of doubt, nothing contained in this Section 6.2 shall excuse a default by the Representative (in its capacity as an Underwriter) in its obligations to purchase the Firm Shares or the Option Shares, if the Over-Allotment Option is exercised hereunder.

Postponement of Closing Date. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased
by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the
right to postpone the Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order to effect
whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the Prospectus or in
any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the Pricing
Disclosure Package or the Prospectus that in the opinion of Company Counsel and counsel to the Representative may thereby be made necessary.
The term “Underwriter” as used in this Agreement shall include any party substituted under this Section 6 with like effect
as if it had originally been a party to this Agreement with respect to such Public Shares.

Additional Covenants.

Board Composition and Board Designations. The Company shall ensure as of the Closing Date that: (i) the qualifications of the
persons serving as members of the Board of Directors and the overall composition of the Board of Directors comply with the Sarbanes-Oxley
Act, with the Exchange Act and with the listing rules of the Exchange or any other national securities exchange, as the case may be,
in the event the Company seeks to have its Public Shares or Representative Warrant Shares listed on another exchange or quoted on an
automated quotation system, and (ii) if applicable, at least one (1) member of the Audit Committee of the Board of Directors qualifies
as an “audit committee financial expert,” as such term is defined under Regulation S-K and the listing rules of the Exchange.

Prohibition on Press Releases and Public Announcements. Except as required by law or rule of the Exchange, the Company shall not
issue press releases or engage in any other publicity, without the Representative’s prior written consent, which consent shall
not be unreasonably withheld, conditioned or delayed, for a period ending at 5:00 p.m., Eastern time, on the first (1st) Business
Day following the twenty-fifth (25th) day after the Closing Date or expiration or termination of this Agreement, other than
normal and customary releases issued in the ordinary course of the Company’s business.

Right of First Refusal. Provided that the Firm Shares are sold in accordance with the terms of this Agreement, the Representative
shall have an irrevocable right of first refusal (the “Right of First Refusal”), for a period of twelve (12) months
after the Closing Date, to act as lead or joint-lead investment banker, lead or joint book-runner, lead or joint placement agent and/or
investment banker/advisor, at the Representative’s sole and exclusive discretion, for each and every future public and private
equity and debt offering, including all equity linked financings (each, a “Subject Transaction”), during such twelve
(12) month period, of the Company, or any successor to or Subsidiary of the Company, on terms and conditions customary to the Representative
for such Subject Transactions. For the avoidance of any doubt, the Company shall not retain, engage or solicit any additional investment
banker, book-runner and/or placement agent in a Subject Transaction without the express written consent of the Representative, which
consent shall not be unreasonably withheld, conditioned or delayed.

The
Company shall notify the Representative of its intention to pursue a Subject Transaction, including the material terms thereof, by providing
written notice thereof by email. If the Representative fails to exercise its Right of First Refusal with respect to any Subject Transaction
within ten (10) calendar days after receipt of such written notice, then the Representative shall have no further claim or right with
respect to the Subject Transaction. The Representative may elect, in its sole and absolute discretion, not to exercise its Right of First
Refusal with respect to any Subject Transaction; provided that any such election by the Representative shall not adversely affect the
Representative’s Right of First Refusal with respect to any other Subject Transaction during the twelve (12) month period agreed
to above.

Tail Financing. The Representative shall be entitled to receive from the Company (i) an aggregate additional fee of seven percent
(7%) of the gross proceeds from any public offering or other financing or capital raising transaction of any kind consummated by the
Company (“Future Financings”) and (ii) warrants, in a form to be reasonably satisfactory to the Representative, to
purchase up to five percent (5%) of the number of any securities sold by the Company in Future Financings (such additional fee and warrants,
the “Future Financing Fees”), in each case to the extent that such financing or capital is consummated with investors
(or any entity under common management or having a common investment advisor) with whom the Company has had a conference call or a meeting
arranged by the Representative so long as such Future Financing is consummated at any time within twelve (12) months after the earlier
to occur of (i) the Closing Date or (ii) the expiration or termination of this Agreement.

Covenant of the Underwriters. The Underwriters covenant with the Company not to take any action that would result in the Company
being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriters
that otherwise would not be required to be filed by the Company thereunder but for the action of the Underwriters.

Effective Date of this Agreement and Termination Thereof.

Effective Date. This Agreement shall become effective when both the Company and the Representative have executed the same and
delivered counterparts of such signatures to the other party.

Termination. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if
any domestic or international event or act or occurrence has materially disrupted, or in your reasonable opinion will in the immediate
future materially disrupt, general securities markets in the United States; (ii) if trading on the New York Stock Exchange or the Nasdaq
Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or
maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority
having jurisdiction; (iii) if the United States shall have become involved in a new war or an increase in major hostilities; (iv) if
a banking moratorium has been declared by a New York State or federal authority; (v) if a moratorium on foreign exchange trading has
been declared which materially adversely impacts the United States securities markets; (vi) if the Company shall have sustained a material
loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss
shall have been insured, will, in your reasonable judgment, make it inadvisable to proceed with the delivery of the Firm Shares (or Option
Shares, as the case may be); (vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder;
or (viii) if the Representative shall have become aware after the date hereof of a Material Adverse Change or an adverse material change
in general market conditions as in the Representative’s reasonable judgment would make it impracticable to proceed with the offering,
sale and/or delivery of the Public Shares or to enforce contracts made by the Underwriters for the sale of the Public Shares.